Package Insert: Information for the Patient
Jorveza 0.5 mg Buccal Tablets
Jorveza 1 mg Buccal Tablets
budesonide
Read this package insert carefully before starting to take this medication, because
it contains important information for you.
1. What is Jorveza and how is it used
2. What you need to know before starting to take Jorveza
3. How to take Jorveza
4. Possible adverse effects
5. Storage of Jorveza
6. Contents of the package and additional information
Jorveza containsthe active ingredient budesonide, a corticosteroid medication that reduces inflammation.
It is used in adults (18 years of age and older) to treat eosinophilic esophagitis, an inflammatory disorder of the esophagus that causes problems swallowing food.
Do not take Jorveza
Warnings and precautions
Consult your doctor or pharmacist before starting to take Jorveza if you have:
If you have any of the aforementioned conditions, you may be at a higher risk of experiencing adverse effects. Your doctor will decide on the necessary measures to take and whether it is still suitable for you to take this medicine.
Jorveza may cause typical side effects of corticosteroid medicines and may affect all parts of the body, particularly if you take this medicine at high doses and for a long time (see section 4).
Additional precautions during treatment with Jorveza
Take the following precautions during treatment with Jorveza, as your immune system may be weakened:
Jorveza may affect the results of adrenal function tests (ACTH stimulation test) requested by your doctor or in a hospital. Inform your doctors that you have been taking Jorveza before any test is performed.
Children and adolescents
Jorveza should not be used in children and adolescents under 18 years of age. The use of this medicine in children under 18 years of age has not yet been studied.
Other medicines and Jorveza
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine. Some of these medicines may increase the effects of Jorveza, so your doctor will make close checks if you are taking these medicines.
Particularly:
Taking Jorveza with food and drink
You should not take grapefruit juice during your treatment with this medicine, as it may worsen its side effects.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.
Do not take this medicine during pregnancy without consulting your doctor first.
Do not take this medicine while breastfeeding unless you have consulted your doctor. Budesonide passes in small amounts into breast milk. Your doctor will help you decide whether to continue treatment and stop breastfeeding or whether to stop treatment during the period when you are breastfeeding your baby.
Driving and operating machines
It is not expected that Jorveza will affect your ability to drive or operate machines.
Jorveza contains sodium
This medicine contains 52 mg of sodium (main component of table salt/for cooking) per daily dose. This is equivalent to 2.6% of the maximum daily sodium intake recommended for an adult.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose for the treatment of acute episodes is two buccal tablets of 1 mg (2 mg of budesonide) per day. Take one buccal tablet of 1 mg in the morning and another buccal tablet of 1 mg in the evening.
The recommended dose for the prevention of new episodes is two buccal tablets of 0.5 mg (1 mg of budesonide) per day or two buccal tablets of 1 mg (2 mg of budesonide) per day, depending on your body's response to treatment. Take one buccal tablet in the morning and another buccal tablet in the evening.
Administration Form
Take the buccal tablet immediately once you take it out of the blister pack.
Take the buccal tablet after a meal.
Place the buccal tablet at the tip of your tongue and close your mouth. Press it gently with your tongue against the palate until it has completely dissolved (this usually takes at least two minutes, but can take up to 20 minutes). Swallow the dissolved material slowly with saliva as the buccal tablet disintegrates.
DO NOT take any liquid with the buccal tablet.
Do not chew or swallow the buccal tablet without dissolving it.
Do not eat, drink, or brush your teeth or rinse your mouth for at least 30 minutes after taking the buccal tablet. Do not use any type of oral solution, spray, or chewable tablet for at least 30 minutes before or after administration of the buccal tablet. This will ensure proper functioning of the medication.
Renal and Hepatic Problems
If you have any kidney or liver problems, inform your doctor. If you have kidney problems, your doctor will decide if Jorveza is suitable for you. If your kidney problems are severe, you should not take Jorveza. If you have any liver disease, you should not take Jorveza.
Treatment Duration
Initially, your treatment should last approximately 6 to 12 weeks.
After the treatment of the acute episode, your doctor will decide for how long and at what dose you should continue treatment, depending on your condition and response to treatment.
If You Take More Jorveza Than You Should
If you have taken too many buccal tablets at once, stick to the prescribed dose when it is time for your next dose. Do not take a lower dose. If you are unsure, contact your doctor. If possible, bring the box and the leaflet with you.
If You Forget to Take Jorveza
If you forget to take a dose, take the next dose at the usual time. Do not take a double dose to compensate for the missed doses.
If You Interrupt Treatment with Jorveza
Talk to your doctor if you want to interrupt or conclude your treatment. It is essential that you do not stop taking your medication without talking to your doctor. Continue taking your medication until your doctor tells you to, even if you feel better.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The following side effects have been reported during the use of Jorveza:
Very common: can affect more than 1 in 10 people
Common: can affect up to 1 in 10 people
Uncommon: can affect up to 1 in 100 people
The following side effects have been reported, which are typical with similar medicines to Jorveza (corticosteroids), so they may also occur with this medicine. The frequency of these events is currently unknown:
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not take this medication after the expiration date that appears on the box and on the blister pack after “CAD”. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C. Store in the original packaging to protect it from light and moisture.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. In this way, you will help protect the environment..
Composition of Jorveza
Jorveza 0.5 mg buccal tablet
Jorveza 1 mg buccal tablet
Appearance of the product and contents of the packaging
Jorveza 0.5 mg buccal tablet
Jorveza 0.5 mg buccal tablets are white, round, and bilayered tablets. They are engraved with “0.5” on one side. They are available in blisters of 20, 60, 90, 100, or 200 buccal tablets.
Jorveza 1 mg buccal tablet
Jorveza 1 mg buccal tablets are white, round, and bilayered tablets. They are available in blisters of 20, 30, 60, 90, 100, or 200 buccal tablets.
Only some packaging sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Dr. Falk Pharma GmbH
Leinenweberstr.5
79108 Freiburg
Germany
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Spain Dr. Falk Pharma España Tel: +34 91 372 95 08 |
Last review date of this leaflet:{MM/AAAA}.
For detailed information about this medicine, please visit the European Medicines Agency website:http://www.ema.europa.eu.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.